Psoriatic Arthritis
Conference Coverage
Mirikizumab beats placebo, secukinumab for psoriasis
If approved, mirikizumab, which binds the p19 subunit of IL-23, would join three other IL-23 drugs already marketed in the United States for...
Conference Coverage
Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring
For patients with psoriasis concerned about their outcome if infected with COVID-19, “there is no evidence to support stopping biologics or...
From the Journals
Non-Whites remain sorely underrepresented in phase 3 psoriasis trials
In 62 of 82 phase 3 trials for psoriasis therapies that included ethnoracial data, 85.8% of participants were white.
News from the FDA/CDC
FDA issues new NSAIDs warning for second half of pregnancy
The FDA action expands on earlier warnings about agents in this drug class, which the FDA previously cautioned about taking after week 30 of...
From the Journals
Guselkumab improvements for psoriatic arthritis persist through 1 year
Results extend previously published 24-week DISCOVER-2 data showing significant improvement over placebo.
Conference Coverage
Study highlights differences between White and Latino patients with psoriasis
Latinos had a higher mean percentage of body surface area involvement in the upper limbs.
From the Journals
Experts assess infection risks for patients on biologics
Different DMARDs “all have fairly similar risks when it comes to ‘classical’ or routine bacterial infections. But when you talk about...
From the Journals
Shingrix effective in older adults with preexisting immune-mediated disorders
The most common immune-mediated disorders in two phase 3 clinical trials of the vaccine were psoriasis, spondyloarthropathy, rheumatoid arthritis...
News from the FDA/CDC
Golimumab approval extended to polyarticular-course JIA and juvenile PsA
The expanded approval to include pediatric indications came as part of a review of a clinical trial mandated by the Pediatric Research Equity Act...
Feature
Pregnancy studies on psoriasis, PsA medications pick up
OTIS has enrolled women with psoriasis and/or psoriatic arthritis in studies of nine medications, most of them biologics.
Conference Coverage
Strategic approach mitigates impact of antidrug antibodies in patients with rheumatic diseases
Consider dose escalation and adding an immunomodulator to overcome the impact of antidrug antibodies in rheumatic disease patients.